Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Subscribe To Our Newsletter & Stay Updated